DE69625877T2 - Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms - Google Patents

Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms

Info

Publication number
DE69625877T2
DE69625877T2 DE69625877T DE69625877T DE69625877T2 DE 69625877 T2 DE69625877 T2 DE 69625877T2 DE 69625877 T DE69625877 T DE 69625877T DE 69625877 T DE69625877 T DE 69625877T DE 69625877 T2 DE69625877 T2 DE 69625877T2
Authority
DE
Germany
Prior art keywords
receptor ligands
ht1a receptor
treat glaucoma
glaucoma
ht1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625877T
Other languages
English (en)
Other versions
DE69625877D1 (de
Inventor
Tomiya Mano
Shunji Sogo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Publication of DE69625877D1 publication Critical patent/DE69625877D1/de
Application granted granted Critical
Publication of DE69625877T2 publication Critical patent/DE69625877T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69625877T 1995-10-25 1996-10-24 Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms Expired - Lifetime DE69625877T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27811995 1995-10-25
JP7582496 1996-03-29

Publications (2)

Publication Number Publication Date
DE69625877D1 DE69625877D1 (de) 2003-02-27
DE69625877T2 true DE69625877T2 (de) 2003-12-24

Family

ID=26416983

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625877T Expired - Lifetime DE69625877T2 (de) 1995-10-25 1996-10-24 Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms

Country Status (3)

Country Link
US (1) US5998467A (de)
EP (1) EP0771563B1 (de)
DE (1) DE69625877T2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
KR20010073153A (ko) 1998-09-18 2001-07-31 제임스 에이. 아노 녹내장 치료용의 세로토닌성 5ｈｔ2 작용제
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
JP2003527423A (ja) * 2000-03-17 2003-09-16 アルコン、インコーポレイテッド 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物
CN1512879A (zh) 2001-06-01 2004-07-14 �Ƹ��� 新的芳氨基丙烷类似物及其用于治疗青光眼的用途
CA2447156A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
PL366636A1 (en) 2001-06-01 2005-02-07 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
US7005448B2 (en) 2001-12-14 2006-02-28 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
WO2004054572A2 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
TW200520760A (en) 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
US10653440B2 (en) * 2005-04-15 2020-05-19 Cook Medical Technologies Llc Tip for lead extraction device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684739A (en) * 1980-12-15 1987-08-04 Mitsubishi Chemical Industries Limited Alkylenedioxybenzene derivatives and acid addition salts thereof
JPH03264528A (ja) * 1990-03-14 1991-11-25 Mitsubishi Kasei Corp 抗不安薬
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5169099A (en) * 1991-12-17 1992-12-08 Yang Chin Hui Adjustable overhead conductor carrier
TW309426B (de) * 1994-03-18 1997-07-01 Senju Pharma Co

Also Published As

Publication number Publication date
DE69625877D1 (de) 2003-02-27
EP0771563A2 (de) 1997-05-07
EP0771563B1 (de) 2003-01-22
US5998467A (en) 1999-12-07
EP0771563A3 (de) 1997-07-30

Similar Documents

Publication Publication Date Title
DE69625877T2 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69609868T2 (de) Neue steroidester zur behandlung von hauterkrankungen
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
ATE219928T1 (de) Verwendung von angiogenese-suppressoren zur hemmung des haarwuchses
DE69500089T3 (de) Behandlung von Geflügel
ATE200863T1 (de) Indolinonverbindungen zur behandlung von krankheiten
DE69831134D1 (de) Behandlung von wasser
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69827126D1 (de) Verwendung von hypothalamus-hemmfaktor zur behandlung von ischämischen herzstörungen
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
DE69614264D1 (de) Behandlung von aluminiumartikeln zur erhöhung der einbrennhärtbarkeit
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69518438T2 (de) Behandlung von übereregten nervenzellenfunktionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition